Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Dept. |
RCV003154848 | SCV003843869 | likely pathogenic | Congenital amegakaryocytic thrombocytopenia | criteria provided, single submitter | clinical testing | ||
Neuberg Centre For Genomic Medicine, |
RCV004763608 | SCV005373598 | likely pathogenic | Congenital amegakaryocytic thrombocytopenia 1 | 2023-06-02 | criteria provided, single submitter | clinical testing | The observed missense c.407C>G (p.Pro136Arg) variant in MPL gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. Another missense variant on the same residue [c.407C>T; p.Pro136Leu] in MPL gene has been reported previously to be disease causing in individuals affected with MPL-related disorders, suggesting that this residue might be of clinical significance (Germeshausen and Ballmaier, 2021). The p.Pro136Arg variant is present with allele frequency of 0.0004% in gnomAD Exomes. This variant has been submitted to the ClinVar database as Likely Pathogenic. The reference amino acid of p.Pro136Arg in MPL is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Pro at position 136 is changed to a Arg changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as a Variant of Uncertain Significance (VUS). |
Fulgent Genetics, |
RCV005029924 | SCV005651167 | likely pathogenic | Primary myelofibrosis; Thrombocythemia 2; Congenital amegakaryocytic thrombocytopenia 1 | 2024-03-07 | criteria provided, single submitter | clinical testing |